Lincus | Home

Developing next-generation microRNA inhibitor therapeutics for prostate cancer

Sponsor: DOD/Department of Defense/Eastern Virginia Medical School

Authors: Raman Bahal

2022-11-01 - 2024-10-31

Nuclease-independent genome editing for neurologic disease

Sponsor: DHHS/NIH/National Institute of Neurological Disorders and Stroke/Auburn University

Authors: Raman Bahal

2020-04-01 - 2022-03-31

Kidney targeted RNA therapies for ADPKD

Sponsor: DHHS/NIH/National Institutes of Health/Yale University School of Medicine

Authors: Raman Bahal

2025-04-01 - 2030-03-31

A Cell Specific MicroRNA Silencing: A Novel Therapeutic Approach for Pulmonary Fibrosis

Sponsor: DOD/Department of Defense/Yale University School of Medicine

Authors: Raman Bahal

2021-09-01 - 2023-08-31

Novel microRNA inhibition to attenuate liver fibrosis

Sponsor: DHHS/NIH/National Institutes of Health/Beth Israel Deaconess Medical Center

Authors: Raman Bahal

2024-09-01 - 2029-08-31

New Generation Site Specific Genome Editing of Hematopoietic Stem Cells for Beta Thalassemia Gene Therapy

Sponsor: Cooley's Anemia Foundation

Authors: Raman Bahal

Funding: $65,000

2018-07-01 - 2021-01-31

Targeted delivery of short antimiRs for lymphoma therapy

Sponsor: DHHS/NIH/National Cancer Institute

Authors: Raman Bahal

2019-09-01 - 2021-08-31

Next Generation Targeting of Multiple OncomiRs for Lymphoma Therapy

Sponsor: DHHS/NIH/National Cancer Institute

Authors: Raman Bahal

2020-07-01 - 2024-06-30

Developing next-generation RNA inhibitors for stroke therapy

Sponsor: DHHS/NIH/National Institute of Neurological Disorders and Stroke/University of Connecticut Health Center

Authors: Raman Bahal

2025-07-01 - 2030-06-30

Anti-miR-21 Therapeutics in Pancreatic Cancer

Sponsor: Pancreatic Cancer Action Network/Beth Israel Deaconess Medical Center

Authors: Raman Bahal

2019-07-01 - 2021-06-30

Targeted delivery of chemically modified RNA inhibitor for prostate cancer therapy

Sponsor: DOD/Department of Defense/Eastern Virginia Medical School

Authors: Raman Bahal

2024-03-01 - 2027-02-28

Developing next-generation chemically modified miRNA inhibitors for cancer and immune therapy

Sponsor: DHHS/NIH/National Institutes of Health/Beth Israel Deaconess Medical Center

Authors: Raman Bahal

2025-04-01 - 2030-03-31

Developing catalytic antisense oligonucleotides for RNA cleavage

Sponsor: American Foundation for Pharmaceutical Education

Authors: Raman Bahal

2023-09-01 - 2024-08-31

Mir-33 Macrophage Specific Silencing, a Novel Therapy for Pulmonary Fibrosis

Sponsor: DHHS/NIH/National Institutes of Health/Yale University School of Medicine

Authors: Raman Bahal

2022-09-01 - 2027-08-31

Targeting DNA-PK Inhibitors to the Tumor Microenvironment by pHLIP

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2024-09-01 - 2029-08-31

PQ4: Targeting multiple oncomiRs for cancer therapy

Sponsor: DHHS/NIH/National Cancer Institute

Authors: Raman Bahal

2019-04-01 - 2024-03-31

Targeting microRNAs to the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs

Sponsor: DHHS/NIH/National Cancer Institute/Beth Israel Deaconess Medical Center

Authors: Raman Bahal

Funding: $886,089

2020-02-07 - 2025-01-31

Targeted delivery of chemically modified RNA inhibitors for prostate cancer therapy

Sponsor: DHHS/NIH/National Institutes of Health/Eastern Virginia Medical School

Authors: Raman Bahal

2025-04-01 - 2030-03-31

Nanoparticle-mediated inhibition of multiple oncomiRs for pediatric glioma therapy

Sponsor: McDonough (Andrew) B+ Foundation

Authors: Raman Bahal

2020-01-01 - 2021-12-31

Endothelium-targeted gamma-peptide nucleic acids to inhibit miR-122-mediated diabetic vasculopathy

Sponsor: DHHS/NIH/National Heart, Lung, and Blood Institute/University of Iowa

Authors: Raman Bahal

2025-04-01 - 2030-03-31

Are you Raman Bahal?

How to update your information.